• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Identifying Outcomes for Sickle Cell Disease Clinical Trials is Aim of coreSCD

The Green Park Collaborative (GPC) is working with the Sickle Cell Disease Association of America (SCDAA) to develop a consensus of desired outcomes to be used in clinical studies evaluating new treatments for sickle cell disease (SCD).

The project, named coreSCD, aims to deliver a list of recommendations on the best outcomes to address the effectiveness and safety of potential therapies for SCD in clinical trials.

Multiple parties will be involved in the initiative, including patients and their families, clinicians, companies developing new SCD therapies, regulators (e.g., the U.S. Food and Drug Administration (FDA), healthcare payers (e.g., private healthcare plans and Medicaid), and sponsors from industry and academia.

One of the project leaders, the Green Park Collaborative (GPC), is a multi-stakeholder forum dedicated to creating disease and technology-specific recommendations to guide the production of evidence to inform both clinical and payment decisions. The forum will be a collaboration of a broad group of national and international partners.